Full-Time

Commercial Business Development Manager

Quantum-Si

Quantum-Si

51-200 employees

Proteomics instrument platform for NGPS sequencing

No salary listed

Remote in Canada

Remote

Remote role; travel 60-80%. Ideally located in Central or Western Canada.

Category
Business & Strategy (1)
Required Skills
Lead Generation
Forecasting
Cold Calling
Requirements
  • Bachelor’s degree in life science preferred
  • 4+ years of quota carrying outside sales
  • Capital sales experience in the research and tools space market with a focus on Proteomics and DNA sequencing
  • Strong relationships in Pharma, biotech and academic research organizations is desired
  • Demonstrated track record in lead generation and prospecting
  • Proven track record of meeting and exceeding sales targets year over year
  • Strong desire to win business and establish long-term customer relationships
  • Confident energetic Hunter mentality
  • Highly adaptable and independent
  • Thrives in a rapidly growing start-up environment and can pivot when necessary with a positive attitude
  • Excellent verbal, written, and computer skills
  • Take initiative with a strong growth mindset
  • Mastery of Miller Heiman Strategic and Conceptual selling
  • Ability to travel 60-80%
  • Work is accomplished proactively without considerable direction and ability to independently resolve complex problems while meeting objectives
  • Ideally located in Central or Western Canada
  • Graduate degree in life sciences strongly preferred
Responsibilities
  • Prospecting and lead generation: Aggressively hunt, identify, and research potential clients across academia, bio/pharma, biotech, and industry
  • Conduct proactive outbound prospecting activities, including cold calling, email outreach, tradeshows and regional events
  • Qualify leads based on their needs, budget, and purchasing authority
  • Nurture relationships through regular follow ups and engagement
  • Closing business: Develop and maintain a robust sales pipeline of qualified opportunities
  • Manage opportunities closely, provide strong forecasting updates, and deliver accurate insights into revenue and adoption
  • Track and prioritize opportunities to ensure timely and efficient sales cycles
  • Create and execute effective sales strategies to close capital deals, exceed sales targets, drive consumable revenue growth
  • Negotiate pricing, terms, and contracts with clients to ensure mutually beneficial agreements that achieve optimal outcomes for both parties
Desired Qualifications
  • Graduate degree in life sciences strongly preferred
  • Mastery of Miller Heiman Strategic and Conceptual selling

Quantum-Si provides proteomics tools that analyze proteins at the single-molecule level using NGPS on a semiconductor chip. The workflow immobilizes peptides on a chip, uses fluorescent recognizers to read amino acids as they are cleaved, and delivers data through an end-to-end platform of benchtop instruments, consumables, and cloud software. It differentiates itself by combining semiconductor-based single-molecule proteomics with an integrated, easy-to-use platform and flexible financing that converts capital expenditures to operating expenses. Its goal is to speed up drug discovery and clinical diagnostics by enabling detailed profiling of proteoforms and post-translational modifications across research, pharma, and diagnostics labs.

Company Size

51-200

Company Stage

IPO

Headquarters

Guilford, Connecticut

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Proteus launches late 2026 with 18 amino acids, expanding proteome coverage.
  • V4 kit and protein barcoding accelerate pharma variant screening applications.
  • $190M cash funds operations to Q2 2028, supporting commercial ramp.

What critics are saying

  • Thermo Fisher and Bruker mass specs dominate with established pharma networks.
  • Platinum stalls at 17 customers yearly, generating only $2.4M 2025 revenue.
  • $98M burn exhausts cash by Q2 2028 without Proteus revenue surge.

What makes Quantum-Si unique

  • Quantum-Si pioneers semiconductor chip for single-molecule protein sequencing.
  • Platinum and Platinum Pro sequencers deliver amino acid resolution on benchtop.
  • Proteus platform integrates automation, higher throughput, and PTM analysis.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Quantum-Si who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Real-time performance monitoring

Remote Work Options

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Mar 3rd, 2026
Quantum-Si targets late-2026 Proteus launch with $215.8M cash runway to Q2 2028

Quantum-Si reported 2025 revenue of $2.4 million and positioned 2026 as a "transition year" focused on developing its Proteus platform, targeting a late-2026 launch. The company ended 2025 with $215.8 million in cash. Management expects approximately $1 million revenue in 2026, with adjusted operating expenses capped at $98 million and cash usage at $93 million, sufficient to fund operations into Q2 2028. The company added 17 new placement customers in 2025 through an expanded instrument access programme. Quantum-Si is building a publication pipeline and developing new applications, including clinical proteomics and rapid pathogen detection, to drive consumable utilization. CEO Jeff Hawkins said the strategic focus on Proteus will enable a stronger commercial ramp from 2027 onwards.

The Associated Press
Mar 3rd, 2026
Quantum-Si reports $451K Q4 revenue, sets Proteus platform price at $425K

Quantum-Si, a proteomics technology company, reported fourth quarter 2025 revenue of $451,000 and full-year revenue of $2.4 million. The company announced its next-generation Proteus platform will be priced at $425,000. For 2026, Quantum-Si provided conservative guidance of approximately $1 million in revenue, reflecting strategic decisions to support Proteus's launch. These include offering upgrade credits on current Platinum Pro system sales and continuing placement programmes, which will moderate near-term revenue but position the platform for stronger long-term adoption. The company reported a full-year 2025 net loss of $101.3 million, including $18.7 million in one-time litigation charges. Adjusted total operating expenses decreased to $86.3 million from $99 million year-over-year. Quantum-Si held $215.8 million in cash and investments as of December 31, 2025, providing runway into second quarter 2028.

AD HOC NEWS Portal Aktiengesellschaft
Oct 1st, 2025
QuantumSi Raises $100M Amid Financial Strain

QuantumSi is facing financial challenges, balancing capital raising efforts against poor revenue and ongoing losses. The company launched a $100 million at-the-market equity program on September 26, 2025, following a 12% weekly drop in share value. This strategy aims to provide financial flexibility with minimal shareholder dilution. Earlier, in July, QuantumSi raised $50 million through a direct placement, extending its operational runway.

Instrument Business Outlook
Sep 8th, 2025
Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing

Quantum-Si announces the launch of V4 sequencing kit, expanding proteome coverage and unlocking new applications for protein sequencing.

Yahoo Finance
Jul 5th, 2025
Quantum-Si Announces $50M Stock Offering

Quantum-Si (QSI) announced a securities purchase agreement with a single institutional investor for 29,940,119 shares of common stock at $1.67 per share, through a registered direct offering. This will result in gross proceeds of approximately $50 million, before deducting expenses. The offering is expected to close around July 8, 2025, pending customary conditions. A.G.P./Alliance Global Partners is the sole placement agent.